Good morning,
Folks we are now in regular order with OTC and the CEO has proven his metal and now we can move on with discussion on the growth aspect of our company.
It is important we articulate what this company does on its business model with respect to the all-important growth aspect that will reflect the share price. This needs to be in the forefront for new members coming in to understand what the future holds.
Once we move into the clinical trials it will start to get really exciting and the company has brought into the fold a superb individual who has a strong resume in this area.
Dr. Mark T. Hamann serves as the Charles and Carol Cooper/SmartState Endowed Chair of Drug Discovery, Biomedical Sciences, and Public Health at the MUSC Colleges of Pharmacy and Medicine1.
He also holds adjunct appointments with The University of Maryland’s Institute of Marine and Environmental Technology and the Bigelow Marine Laboratory in Maine1.
Recent Appointment:
Branded Legacy, Inc., a trailblazing BioTech holdings company, recently announced the strategic acquisition of Sycamore BioPharma, Inc.
As part of this acquisition, Dr. Mark T. Hamann has been appointed as the Director of Clinical Trials at Branded Legacy23.
His expertise will enhance efforts in developing novel pharmaceuticals and streamline the FDA approval process, particularly in clinical trials2.
Collaboration and Synergies:
The collaboration between Branded Legacy and Sycamore BioPharma aims to unlock synergies across various business facets.
Leveraging Branded Legacy’s web properties, brand management, and marketing expertise, they intend to maximize the reach and impact of Sycamore BioPharma’s groundbreaking wellness solutions2.
Overall, Dr. Mark Hamann’s addition to Branded Legacy’s roster is a significant step toward advancing pharmaceutical research and development, benefiting both the company and the broader healthcare industry.
Today we will move higher and probably touch .007. The volume will be awesome with many new shareholders getting in on the action. I expect some sort of announcement coming that will further the manufacturing aspect of our company.
When we move out of the gate, the move into .006 will be aggressive so for sake of stabilization wait 15m for it to settle in. Don't worry about missing out, there will be plenty of moments to acquire and most on this thread should've averaged in yesterday with the downdraft that provided just unforeseen buying opportunity. If I may say on an unfortunate misunderstanding. However, we are now good to go and enjoy the current climate, because folk's, it is going to just plain and simple, get really exciting for the next few months.
Have a good day.
varok
Bullish
AI
